SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Show more

Location: 7 Times Square, New York, NY, 10036, United States | Website: https://www.sellaslifesciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

187.4M

52 Wk Range

$0.77 - $2.27

Previous Close

$1.78

Open

$1.80

Volume

1,550,438

Day Range

$1.75 - $1.82

Enterprise Value

162.9M

Cash

25.3M

Avg Qtr Burn

-7.84M

Insider Ownership

0.32%

Institutional Own.

25.54%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Galinpepimut-S Details Blood cancer, Cancer, Acute myeloid leukemia Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) + Brukinsa Details Cancer, Blood cancer, Diffuse large B cell lymphoma	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) +/- venetoclax & azacitidine Details Acute myeloid leukemia	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) Details Blood cancer, Cancer, Lymphoma, Peripheral T-cell Lymphomas	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Galinpepimut-S + KEYTRUDA (pembrolizumab) Details Ovarian cancer, Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SLS009 (GFH009) Details Cancer, Blood cancer, Pediatric Sarcomas	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Galinpepimut-S + OPDIVO (nivolumab) Details Cancer, Malignant pleural/peritoneal mesothelioma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nelipepimut-S Details Solid tumor/s, Cancer, Breast cancer, Triple-negative breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.